Ng-ACP is a potential dual target for tackling gonococcal infections, as inclusion of this protein within a multicomponent vaccine could induce antibodies that are bactericidal and could also prevent the gonococcus from inhibiting the lytic activity of a mucosal innate defense molecule. Here, NRGN is linked to gonorrhea.